Between April and Nov, 2020, more than 11 600 voluntary, in participants who received two standard doses, vaccine efficacy was 62%, and in participants who received a low dose followed by a standard dose, efficacy was 90%. Around 08% of the volunteers in AstraZeneca’s studies were around 56 and 69 years old and 04% were above 70.